Benzinga
Benzinga
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Benzinga
mardi, octobre 20
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Health Catalyst Inc
HCAT
NASDAQ
Liste de surveillance
Get Report
Trade with Public
Get Report
Trade with Public
$1.71
-0.015
-0.87%
Dern. MÀJ: Oct 16, 6:24 PM
$1.75
0.0249
1.44%
Get Report
Aperçu
Actualités
Prévisions de résultats
Événements
Objectifs de cours
Données financières
Sentiment
Actionnariat
Comparer
Options
Rapport sur les stocks
Privacy Manager
Health Catalyst Financials
Health Catalyst (HCAT) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
Health Catalyst Shares Tumble Overnight: What Investors Need to Know
Health Catalyst stock fell after hours after reporting Q2 results and issuing weaker third-quarter revenue guidance.
Tanya Rawat
PRO
Health Catalyst Sees FY2026 Sales $246.000M-$249.000M vs $260.780M Est
Health Catalyst (NASDAQ:HCAT) sees FY2026 sales of $246.000 million-$249.000 million vs $260.780 million analyst estimate.
Benzinga Newsdesk
PRO
Health Catalyst Sees Q3 Sales $55.000M-$56.000M vs $62.159M Est
Health Catalyst (NASDAQ:HCAT) sees Q3 sales of $55.000 million-$56.000 million vs $62.159 million analyst estimate.
Benzinga Newsdesk
PRO
Health Catalyst Q2 Adj. EPS $0.04 Beats $0.03 Estimate, Sales $70.487M Beat $69.059M Estimate
Health Catalyst (NASDAQ:HCAT) reported quarterly earnings of $0.04 per share which beat the analyst consensus estimate of $0.03 by 33.33 percent. This is unchanged from the same period last year. The company reported
Benzinga Newsdesk
PRO
Health Catalyst Sees Q2 Sales $68.000M-$70.000M vs $70.752M Est
Health Catalyst (NASDAQ:HCAT) sees Q2 sales of $68.000 million-$70.000 million vs $70.752 million analyst estimate.
Benzinga Newsdesk
PRO
Health Catalyst Q1 Adj. EPS $0.02, Inline, Sales $70.756M Beat $69.171M Estimate
Health Catalyst (NASDAQ:HCAT) reported quarterly earnings of $0.02 per share which met the analyst consensus estimate. This is a 100 percent increase over earnings of $0.01 per share from the same period last year. The
Benzinga Newsdesk
